- Home
- GAME vs ANL Comparison
GAME vs ANL Comparison
Compare GAME & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ANL
- Stock Information
- Founded
- GAME 2011
- ANL 2004
- Country
- GAME United States
- ANL Cayman Islands
- Employees
- GAME N/A
- ANL N/A
- Industry
- GAME
- ANL
- Sector
- GAME
- ANL
- Exchange
- GAME Nasdaq
- ANL Nasdaq
- Market Cap
- GAME 66.6M
- ANL 61.8M
- IPO Year
- GAME 2009
- ANL 2023
- Fundamental
- Price
- GAME $0.80
- ANL $1.80
- Analyst Decision
- GAME Strong Buy
- ANL Hold
- Analyst Count
- GAME 2
- ANL 1
- Target Price
- GAME $3.00
- ANL N/A
- AVG Volume (30 Days)
- GAME 3.1M
- ANL 11.3K
- Earning Date
- GAME 11-13-2025
- ANL 10-21-2025
- Dividend Yield
- GAME N/A
- ANL N/A
- EPS Growth
- GAME N/A
- ANL N/A
- EPS
- GAME N/A
- ANL N/A
- Revenue
- GAME $93,375,339.00
- ANL N/A
- Revenue This Year
- GAME $2.32
- ANL N/A
- Revenue Next Year
- GAME $26.42
- ANL N/A
- P/E Ratio
- GAME N/A
- ANL N/A
- Revenue Growth
- GAME 54.19
- ANL N/A
- 52 Week Low
- GAME $0.50
- ANL $1.10
- 52 Week High
- GAME $2.87
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- GAME 55.33
- ANL 55.55
- Support Level
- GAME $0.77
- ANL $1.70
- Resistance Level
- GAME $0.86
- ANL $1.82
- Average True Range (ATR)
- GAME 0.04
- ANL 0.09
- MACD
- GAME 0.02
- ANL -0.00
- Stochastic Oscillator
- GAME 76.84
- ANL 60.33
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.